230 related articles for article (PubMed ID: 11798498)
1. Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.
Druker BJ
J Hematother Stem Cell Res; 2001 Dec; 10(6):721-4. PubMed ID: 11798498
[No Abstract] [Full Text] [Related]
2. Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award.
Claiborn K
J Clin Invest; 2011 Apr; 121(4):1227-8. PubMed ID: 21630503
[No Abstract] [Full Text] [Related]
3. Part I: Milestones in personalised medicine--imatinib.
Gambacorti-Passerini C
Lancet Oncol; 2008 Jun; 9(6):600. PubMed ID: 18510992
[No Abstract] [Full Text] [Related]
4. Imatinib (Gleevec) as a paradigm of targeted cancer therapies.
Druker B
Keio J Med; 2010; 59(1):1-3. PubMed ID: 20375651
[No Abstract] [Full Text] [Related]
5. Chronic myeloid leukemia. Sceptical scientists.
Druker BJ
Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
[No Abstract] [Full Text] [Related]
6. [Treatment of chronic myeloid leukemia with imatinib. A case of translational medicine].
Dosne Pasqualini C
Medicina (B Aires); 2010; 70(3):293-6. PubMed ID: 20529782
[No Abstract] [Full Text] [Related]
7. Cancer treatment. New drugs, new hope.
Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447
[No Abstract] [Full Text] [Related]
8. STI571: a magic bullet?
Verweij J; Judson I; van Oosterom A
Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
[No Abstract] [Full Text] [Related]
9. A hope for the future.
Silver RT
Cancer Invest; 2003 Jun; 21(3):486. PubMed ID: 12901295
[No Abstract] [Full Text] [Related]
10. [Chronic myeloid leukemia and imatinib mesylate therapy].
Chrobák L
Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
[No Abstract] [Full Text] [Related]
11. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
12. From the Food and Drug Administration.
Schwetz BA
JAMA; 2001 Jul; 286(1):35. PubMed ID: 11434814
[No Abstract] [Full Text] [Related]
13. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
Sawyers CL
Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882
[TBL] [Abstract][Full Text] [Related]
14. Thriving with chronic myeloid leukaemia.
Morris RH
Lancet; 2001 Dec; 358 Suppl():S12. PubMed ID: 11784561
[No Abstract] [Full Text] [Related]
15. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
Richardson MW; Grewal SS
Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
[No Abstract] [Full Text] [Related]
16. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
17. Imatinib and chronic-phase leukemias.
Boros LG; Lee WN; Cascante M
N Engl J Med; 2002 Jul; 347(1):67-8. PubMed ID: 12097546
[No Abstract] [Full Text] [Related]
18. Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia.
Sawyers CL
Semin Hematol; 2001 Jul; 38(3 Suppl 8):1-2. PubMed ID: 11526594
[No Abstract] [Full Text] [Related]
19. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
Gambacorti C
Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
[No Abstract] [Full Text] [Related]
20. 3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I
Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
[No Abstract] [Full Text] [Related]
[Next] [New Search]
